Medicine:Molecular tumor board
A Molecular Tumor Board (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity.[1] It has also been called a Sequencing Tumor Board[2] and it is characterized by the in-depth application of molecular analysis (e.g. genomics and transcriptomics) for a single patient.[2] Molecular Tumor Boards are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas.[1] The boards are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists.[1] MTBs are considered to improve clinical outcomes for patients with tumors with unique molecular profiles.[3]
Molecular Tumour Boards have been used by a number of institutions, like the Dartmouth–Hitchcock Medical Center, the Johns Hopkins Hospital[4] and the Moffitt Cancer Center.[5]
References
- ↑ 1.0 1.1 1.2 "Molecular Tumor Boards in Clinical Practice". Trends in Cancer 6 (9): 738–744. September 2020. doi:10.1016/j.trecan.2020.05.008. PMID 32517959.
- ↑ 2.0 2.1 "Personalized oncology through integrative high-throughput sequencing: a pilot study". Science Translational Medicine 3 (111): 111ra121. November 2011. doi:10.1126/scitranslmed.3003161. PMID 22133722.
- ↑ "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications 11 (1): 4965. October 2020. doi:10.1038/s41467-020-18613-3. PMID 33009371. Bibcode: 2020NatCo..11.4965K.
- ↑ "Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board". JCO Precision Oncology 2017 (1): 1–19. November 2017. doi:10.1200/po.16.00046. PMID 30003184.
- ↑ "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience". The Oncologist 22 (2): 144–151. February 2017. doi:10.1634/theoncologist.2016-0195. PMID 28179575.
 |  |
